Page last updated: 2024-09-03

gefitinib and pedunculoside

gefitinib has been researched along with pedunculoside in 1 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (pedunculoside)	Trials (pedunculoside)	Recent Studies (post-2010) (pedunculoside)
5,231	566	2,919	16	0	12

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Fan, Q; Gao, H; Han, S; Li, S; Liang, X; Xiao, Y; Xu, Q; Xu, Z; Yang, S; Yuan, R	1

Other Studies

1 other study(ies) available for gefitinib and pedunculoside

Article	Year
Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Jul-25, Volume: 116 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Lung Neoplasms; Mice; NF-E2-Related Factor 2; Reactive Oxygen Species; Transforming Growth Factor beta1; Triterpenes	2023

Article

Year

Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Jul-25, Volume: 116

Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Lung Neoplasms; Mice; NF-E2-Related Factor 2; Reactive Oxygen Species; Transforming Growth Factor beta1; Triterpenes

2023